Home / Business and Economy / India Opens Doors for Global Phase I Drug Trials
India Opens Doors for Global Phase I Drug Trials
12 Nov
Summary
- India is considering allowing multinational companies to conduct Phase I clinical trials.
- This move aims to attract global drug innovation and development to India.
- India has strengthened its manufacturing compliance over the past two years.
India is actively exploring modifications to its pharmaceutical regulatory framework to attract multinational corporations for clinical trials. Discussions are underway to permit these companies to conduct Phase I, first-in-human trials within India.
This strategic move is intended to significantly enhance India's standing as a destination for global drug innovation and development. Concurrently, the country has focused on strengthening its manufacturing compliance over the last two years.
Allowing multinational firms to conduct early-stage trials could expedite approvals for new products, addressing a current lag in regulatory reviews. While formal processes and safeguards are still being defined, the existing framework for Indian companies' Phase I trials might be extended to foreign entities.
Australia has emerged as a competitive example, offering swift application clearances and financial incentives for clinical trials. India's large population presents a unique advantage for new drug research, potentially aligning it with other key trial locations like China, Australia, and the US.
